EyePoint Pharmaceuticals (NasdaqGM:EYPT) Conference March 25, 2026 08:45 AM ET Company ParticipantsGeorge O. Elston - EVP and CFOJay S. Duker - President and CEOConference Call ParticipantsLisa Walter - Biotechnology AnalystLisa WalterGood morning, everyone. I'm Lisa Walter, biotech analyst here at RBC Capital Markets. Thanks for joining us at RBC's Ophthalmology Conference. This session, we have Jay Duker, Managing Director and Chief Executive Officer, and George Elston, EVP, and Chief Financial Officer fr ...

Summary of Regenxbio FY Conference Call (March 10, 2026) Company Overview - **Company**: Regenxbio (NasdaqGS: RGNX) - **Key Products**: DUPIXENT, EYLEA, linvoseltamab, fianlimab, LIBTAYO Core Industry Insights DUPIXENT - **Sales Performance**: Achieved $17.8 billion in sales for the previous year, representing a 32% year-over-year growth [8][9] - **Market Position**: Positioned well with growth anticipated across all 9 FDA-approved indications, including recent launches for chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) [3][9] - **Launch Success**: Strong start for CSU and significant unmet need addressed by COPD, with robust payer coverage and enthusiasm from pulmonologists [10][11] - **Life Cycle Management**: Plans for new long-acting formulations (Super Dupie) and other antibodies targeting IL-4 and IL-13 to sustain revenue against emerging competition [19][20][21] EYLEA - **Sales Growth**: Reported $506 million in sales for EYLEA HD, up 66% year-over-year [22] - **Product Enhancements**: Anticipation of prefilled syringe approval expected to enhance operational workflows in retinal clinics [22][23] - **Market Dynamics**: Expectation of double-digit sequential decline in EYLEA sales due to biosimilar competition, while transitioning patients to EYLEA HD [25][26] Linvoseltamab - **Market Opportunity**: Targeting a refractory patient population in fourth-line myeloma, with potential expansion into earlier lines of therapy [34][35] - **Patient Population**: Approximately 3,000-4,000 patients in the U.S. for the fourth-line setting, with aspirations to capture a larger share of the $30 billion market [35][36] Obesity Program - **Product Development**: Olatorepatide shows promising results with 19% weight loss in pivotal data from China, with plans for U.S. phase 3 studies [27][28] - **Combination Therapy**: Exploring co-formulation of alirocumab (Praluent) with olatorepatide to address dual needs of weight loss and LDL cholesterol reduction [29][30] Key Catalysts and Future Outlook - **Pipeline Readouts**: Anticipated interim readouts for geographic atrophy and PNH towards the end of the year, with pivotal data from Factor XI expected in the first half of next year [39][40] - **Competitive Landscape**: Monitoring competitor readouts for insights and potential impacts on Regenxbio's strategies [40] Additional Insights - **Regulatory Risks**: Forward-looking statements are subject to risks and uncertainties, with no obligation to update based on new information [5] - **Market Education**: Emerging competition in atopic dermatitis is seen as beneficial for DUPIXENT by increasing market education and awareness [17][18] This summary encapsulates the key points discussed during the conference call, highlighting Regenxbio's strategic positioning, product performance, and future opportunities within the biopharmaceutical industry.

Summary of the Conference Call Company Overview - **Company**: Surrozen - **Industry**: Biotechnology, specifically focusing on retinal vascular diseases - **Key Products**: SZN-8141 and SZN-413, targeting Wnt biology and VEGF inhibition Core Points and Arguments Company Strengths - Surrozen combines expertise in Wnt biology with multivalent antibody technology, focusing on retinal vascular diseases [2][3] - Unique approach of combining Wnt, VEGF, and IL-6 inhibition in a single molecule, SZN-8141, which is currently the only known product to do so [2][3] Challenges - The company is in the execution phase, with an IND filing planned for 2026 [3] - Current therapies primarily slow disease progression rather than improve visual outcomes, highlighting the need for innovative solutions [3] Opportunities - Potential to improve visual and anatomic outcomes in diabetic macular edema and wet AMD [3] - The ability to stimulate normal vessel growth in the retina, which is a unique aspect of Wnt biology [4] Product Details - **SZN-8141**: An IgG-based multispecific molecule that activates Wnt signaling by binding to Fzd4 and LRP5 receptors, while also acting as a VEGF trap [9][10] - Preclinical data indicates that SZN-8141 shows synergistic benefits compared to existing therapies like EYLEA [12] Clinical Development - The first human trial design is still being finalized, with an emphasis on determining dosing and patient endpoints [18][19] - The company plans to conduct a phase 1b/2a study with ascending doses to evaluate visual acuity and retinal drying [19] Competitive Landscape - Merck's program, which is similar, has two phase 3 trials ongoing, with top-line data expected in September 2023 [26] - Surrozen aims to demonstrate that combining multiple mechanisms in one antibody will yield better outcomes than single-target therapies [27] Financial Aspects - Surrozen has a cash balance of approximately $80 million, with additional funding expected upon IND clearance [102] - The company is currently self-funding its clinical studies for SZN-8141 and SZN-8143, indicating a strong financial position for development [96] Safety and Risks - No theoretical risks associated with combining VEGF and Wnt inhibition have been identified, although immunogenicity risks are always a concern with large molecules [42][87] - Recent studies have shown some retinal vascular occlusions, but these are not deemed above the expected background rate [88] Future Directions - Surrozen plans to advance both SZN-8141 and SZN-8143, with SZN-8143 targeting more inflammatory-driven diseases [63][64] - The company is optimistic about the potential for IL-6 inhibition to provide additive benefits in retinal diseases [68][70] Additional Important Information - The market for retinal diseases is becoming increasingly attractive, with growing strategic interest from larger pharmaceutical companies [100][101] - Surrozen's strategy includes leveraging the small number of retinal specialists in the U.S. for commercialization, making it a tractable market for a small biotech firm [96][97]

Core Insights - Regeneron has a compelling story to share, particularly regarding its clinical programs that are not currently reflected in its valuation [3] Company Overview - The company is actively working on various clinical programs aimed at bringing new treatments to patients, which are not being fully appreciated in the market [3] Conference Participation - Regeneron executives, including Chris Fenimore and Ryan Crowe, participated in the TD Cowen Conference, indicating strong attendance and interest in their presentation [2]

Summary of EyePoint Pharmaceuticals FY Conference Call Company Overview - **Company**: EyePoint Pharmaceuticals (NasdaqGM:EYPT) - **Industry**: Biotechnology, specifically focusing on ophthalmology and treatments for retinal diseases Key Highlights - **Phase 3 Trials Initiation**: EyePoint announced the dosing of patients in both phase 3 diabetic macular edema (DME) trials, COMO and CAPRI, achieving their timeline goal of first patient dosing in Q1 2026 [2][3] - **Market Opportunity**: The DME market is projected to reach $3 billion annually in the U.S. EyePoint aims to capture a significant share of this market with their sustained release TKI, DURAVYU, which is unique in the DME space [2][3] - **Trial Design**: Each DME trial will enroll approximately 240 patients, leveraging safety data from previous wet AMD trials to maintain a lower patient count while ensuring robust results [3][5] Core Points and Arguments - **Efficacy and Safety**: DURAVYU demonstrated superior results compared to EYLEA in phase 2 trials, with patients showing better visual acuity and less fluid accumulation [4][21] - **Recruitment Success**: The company successfully recruited for their wet AMD trials in about 7 months, indicating strong interest and confidence from clinical sites, which will also be utilized for the DME trials [5][6] - **Safety Profile**: No serious adverse events (SAEs) have been reported in the 191 patients treated across four trials, reinforcing confidence in the safety of DURAVYU [22] Mechanistic Insights - **IL-6 Blockade Discovery**: EyePoint identified that DURAVYU acts as a potent blocker of JAK1, which is linked to IL-6 activity, potentially providing additional therapeutic benefits in treating DME and wet AMD [15][19] - **Differentiation from Competitors**: EyePoint's approach combines anti-VEGF and anti-IL-6 mechanisms, which may offer advantages over existing treatments [19][60] Phase 3 Expectations - **Non-Inferiority and Treatment Burden**: The primary endpoint for phase 3 trials is non-inferiority to EYLEA, with a secondary focus on reducing treatment burden. A 60% reduction in treatment burden is anticipated compared to EYLEA's regimen [28][29] - **Supplementation Criteria**: Improved criteria for supplemental injections are expected to lead to fewer unnecessary supplements in the phase 3 trials, enhancing overall treatment efficiency [32][33] Market Potential - **Combined Market Size**: The total market opportunity for wet AMD and DME is estimated at $15 billion globally, with EyePoint targeting a significant share if they can demonstrate non-inferiority and additional benefits [68] - **Long-term Patient Compliance**: The sustained release nature of DURAVYU is expected to improve patient compliance and outcomes, addressing a critical issue in chronic disease management [49][50] Additional Insights - **Regulatory Strategy**: EyePoint is preparing for potential NDA submissions following the completion of their trials, with expectations of a streamlined process due to the identical nature of the studies [38][39] - **Future Developments**: The company plans to present more data at upcoming conferences, which may further validate their findings and enhance market perception [19][68] This summary encapsulates the key points discussed during the conference call, highlighting EyePoint Pharmaceuticals' strategic direction, market potential, and innovative approaches in the treatment of retinal diseases.

Merck & Co (NYSE:MRK) FY Conference Summary Company Overview - **Company**: Merck & Co - **Event**: Sixth Annual Healthcare Conference - **Date**: March 03, 2026 - **Key Speakers**: Caroline Litchfield (CFO), Dr. Dean Li (President of Merck Research Laboratories) Key Points Industry and Company Transformation - Merck is transforming its portfolio with the launch of several new products including WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX, aiming for over 20 new growth drivers in human health [2][3] - The company anticipates a commercial opportunity exceeding $70 billion from these products [2] - The animal health business is expected to double its revenues by the mid-2030s [2] Pipeline and Product Development - Merck has a robust early-stage pipeline with six late-stage pipeline readouts expected in 2026 and 2027 [4] - Key products in the pipeline include: - **sac-TMT** and **I-DXd**: Important for cancer treatment, with ongoing trials [7][17] - **MK-3000**: A new mechanism for treating diabetic macular edema and neovascular AMD, targeting patients who do not respond to existing treatments [10][11] - **Islatravir**: A once-weekly oral treatment for HIV, showing over 90% adherence and efficacy in trials [14] - **SAC-TMT**: Differentiated from existing Trop-2 ADCs, with promising data from trials in lung and breast cancer [15][17] Market Dynamics and Competitive Landscape - Merck is confident in navigating the loss of exclusivity for KEYTRUDA, expecting a shallow revenue dip followed by strong growth [3] - The company is focusing on the oral PCSK9 therapy, which is anticipated to catalyze market growth due to guideline changes [25][26] - Merck's inclisiran is expected to launch in Q1 2027, with strong clinical data supporting its efficacy [30] Future Outlook - Merck aims to diversify its product offerings beyond KEYTRUDA, Gardasil, and Animal Health, focusing on first-in-class and best-in-class innovations [61] - The company is committed to driving growth and delivering returns for shareholders through its evolving product portfolio [61] Other Notable Mentions - **Gardasil**: Expected to maintain stable revenues in 2026, with a focus on the mid-adult segment [57] - **MK-1406**: An antiviral conjugate for influenza, targeting immunocompromised patients, with a significant market opportunity [20] - **Nemtabrutinib**: A competitive entry in the CLL market, with a focus on diversifying oncology offerings [48] Conclusion Merck is positioned for significant growth through its diverse pipeline and strategic product launches, with a strong emphasis on innovation and market adaptation. The company is optimistic about its future, aiming to transform its business model and enhance shareholder value.

Summary of Ocular Therapeutix FY Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Event**: FY Conference on March 02, 2026 - **Key Speaker**: Pravin U. Dugel, CEO Core Industry Insights - **Industry**: Biopharmaceuticals, specifically focusing on retinal diseases and treatments - **Key Product**: AXPAXLI, a drug aimed at treating retinal diseases, with a focus on its superiority over existing anti-VEGF treatments Key Points and Arguments 1. **Positive Study Outcome**: The SOL-1 study achieved a positive outcome, marking the first superiority study in the retina field to meet its primary endpoint, with a p-value of 0.0006, indicating statistical significance [2][8][25] 2. **Study Design**: The study was conducted under a Special Protocol Assessment (SPA) from the FDA, making it unique and unprecedented in its design [2][25] 3. **Data Transparency**: Ocular Therapeutix provided extensive data (129 slides) to address questions and concerns raised post-study announcement, emphasizing the consistency of the data across various analyses [3][4][5] 4. **Visual Acuity Loss**: The study highlighted the time it takes for significant vision loss to occur, with a focus on the clinical significance of the OCT results, which showed a high degree of disease control [8][20] 5. **Rescue Patients Analysis**: The analysis of patients who required rescue injections indicated that the AXPAXLI drug performed well even in a biased patient population, with results still being favorable compared to EYLEA [17][19] 6. **Superiority Label Importance**: The CEO emphasized the potential for AXPAXLI to receive a superiority label, which would protect its pricing and market position against competitors, particularly in a landscape filled with non-inferiority studies [25][27] 7. **Community vs. Clinical Trial Performance**: The CEO expressed confidence that AXPAXLI would perform better in real-world settings than in clinical trials, as the trial population was designed to lose vision [32][33] 8. **Regulatory Pathway**: Ocular Therapeutix is optimistic about submitting for approval based on a single trial, citing the robustness of their data and the SPA agreement with the FDA [64][65] 9. **Broad Label Expectations**: The company anticipates a broad label for diabetic retinopathy and diabetic macular edema, which would encompass all patients with these conditions [66][67] Additional Important Insights - **Safety Profile**: The CEO addressed concerns regarding floaters and cataracts, clarifying that reported floaters were drug particles observed by physicians and did not affect vision [60][63] - **Market Positioning**: The company aims to differentiate AXPAXLI from competitors like EYLEA and Vabysmo, highlighting its longer duration of effect and potential for better patient outcomes [48][49] - **Physician Perspectives**: There is a disconnect between analysts' focus on labeling and physicians' practical use of the drug, with physicians prioritizing treatment efficacy over label specifics [22][23][27] This summary encapsulates the key discussions and insights from the Ocular Therapeutix conference call, focusing on the company's recent study outcomes, product positioning, and future regulatory strategies.

Core Insights - Ocular Therapeutix has appointed David W. Robinson as Global Chief Commercial Officer, which is expected to enhance the company's strategic positioning for the global launch of AXPAXLI™ for wet age-related macular degeneration and non-proliferative diabetic retinopathy, pending approval [1][2][3] Company Overview - Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience with its investigational product candidate AXPAXLI™ (OTX-TKI), currently in Phase 3 clinical trials for wet AMD and NPDR [8] - The company also markets DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain, and is developing OTX-TIC, a travoprost intracamreal hydrogel for glaucoma [9] Leadership and Experience - David W. Robinson has a strong background in ophthalmology, having previously served as Chief Marketing Officer at Merck and played a key role in the launch of EYLEA at Regeneron, which is recognized as a significant success in the retina market [2][4][5] - Robinson's experience includes strategic launch planning, global market access, and building commercial teams, which will be crucial for Ocular's upcoming product launches [3][5] Product Potential - AXPAXLI is viewed as having global potential, with opportunities to improve patient outcomes and streamline logistics for healthcare providers, while also offering a predictable profile for payors [3] - The product candidate is positioned to address significant unmet needs in retinal diseases, with registrational programs already in progress [3][8]

Core Insights - Longleaf Partners Fund returned 3.35% in Q4 2025, outperforming the S&P 500's 2.66% but underperforming the Russell 1000 Value Index's 3.81% [1] - The firm faced challenges in 2025, with only 5% of the portfolio gaining 20% or more compared to 35% of the S&P 500 [1] - The firm emphasizes strengthening portfolio outcomes over chasing short-term winners, advocating for a focus on real companies during speculative periods [1] Company Focus: Regeneron Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. had a one-month return of -5.94% and a 52-week gain of 7.55%, with a market capitalization of $77.693 billion [2] - Initially a detractor, Regeneron became a contributor in Q4 2025, with a phased buy-in strategy proving effective [3] - The company is well-positioned in allergic diseases and oncology, with a focus on its pipeline value rather than just EYLEA, which constitutes less than 20% of its value [3] - Regeneron has a net cash balance sheet, strong owner-partners, and has avoided large M&A, opting for significant share repurchases in 2025 [3]

Core Viewpoint - Oculentis Biopharma-B (01477) has received approval from the National Medical Products Administration of the People's Republic of China for OT-702, a biosimilar to EYLEA, for the treatment of adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1][2] Group 1 - OT-702 is developed in collaboration with Shandong Boan Biotechnology Co., Ltd., which is listed on the Hong Kong Stock Exchange [1] - The partnership agreement established in October 2020 includes joint efforts to advance OT-702's Phase III clinical trials, granting the company exclusive rights for promotion and commercialization in China [1] Group 2 - OT-702 functions as a soluble decoy receptor that binds to VEGF-A, VEGF-B, and P1GF, blocking downstream signaling pathways of VEGFR, inhibiting neovascularization, and reducing vascular permeability [2] - As a biosimilar to EYLEA, OT-702 can potentially be approved for all indications for which EYLEA has been approved in China, including nAMD and DME [2]